| Entry |
|
|---|
| Name |
Atomoxetine hydrochloride (JAN/USP);
Tomoxetine hydrochloride;
Strattera (TN) |
|---|
| Product |
|
|---|
| Generic |
ATOMOXETINE (American Health Packaging), ATOMOXETINE (Aurobindo Pharma Limited), ATOMOXETINE (Burel Pharma), ATOMOXETINE (Cadila Healthcare Limited), ATOMOXETINE (Camber Pharmaceuticals), ATOMOXETINE (Dr. Reddy's Laboratories Limited), ATOMOXETINE (Glenmark Pharmaceuticals), ATOMOXETINE (Major Pharmaceuticals), ATOMOXETINE (Northstar Rx LLC), ATOMOXETINE (REMEDYREPACK), ATOMOXETINE (Rising Pharmaceuticals), ATOMOXETINE (Teva Pharmaceuticals USA), ATOMOXETINE (Zydus Pharmaceuticals (USA)), ATOMOXETINE HYDROCHLORIDE (A-S Medication Solutions), ATOMOXETINE HYDROCHLORIDE (A-S Medication Solutions), ATOMOXETINE HYDROCHLORIDE (A-S Medication Solutions), ATOMOXETINE HYDROCHLORIDE (A-S Medication Solutions), ATOMOXETINE HYDROCHLORIDE (A-S Medication Solutions), ATOMOXETINE HYDROCHLORIDE (Apotex Corp.), ATOMOXETINE HYDROCHLORIDE (AvPAK), ATOMOXETINE HYDROCHLORIDE (AvPAK), ATOMOXETINE HYDROCHLORIDE (Golden State Medical Supply), ATOMOXETINE (Prasco Laboratories) |
|---|
| Formula |
C17H21NO. HCl
|
|---|
| Exact mass |
291.139
|
|---|
| Mol weight |
291.8157
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG03085 Selective norepinephrine reuptake inhibitor (NRI)
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
|
|---|
| Remark |
| Therapeutic category: | 1179 |
| Product (DG00970): | D02574<JP/US> |
|
|---|
| Efficacy |
Stimulant (central), Selective noradrenaline reuptake inhibitor (NRI) |
|---|
| Disease |
Attention-deficit/hyperactivity disorder [DS: H01895] |
|---|
| Comment |
Fluoxetine derivative
Treatment of attention deficit hyperactivity disorder (ADHD)
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07234 | Neurotransmitter transporter inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06BA Centrally acting sympathomimetics
N06BA09 Atomoxetine
D02574 Atomoxetine hydrochloride (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Attention Deficit Hyperactivity Disorder Agents, Non-amphetamines
Atomoxetine
D02574 Atomoxetine hydrochloride (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
117 Psychotropics
1179 Others
D02574 Atomoxetine hydrochloride (JAN/USP)
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A2 (NAT1)
D02574 Atomoxetine hydrochloride (JAN/USP) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02574
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02574
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02574
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02574
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D02574
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 20
1 C8x C 11.5500 -14.3500
2 C8x C 11.5500 -15.7500
3 C8x C 12.7624 -16.4500
4 C8x C 13.9749 -15.7500
5 C8y C 13.9749 -14.3500
6 C8y C 12.7624 -13.6500
7 C1a C 12.7624 -12.2502
8 O2a O 15.2124 -13.6500
9 C1c C 16.4249 -14.3500
10 C1b C 17.6373 -13.6500
11 C1b C 18.8497 -14.3500
12 N1b N 20.0622 -13.6500
13 C1a C 21.2746 -14.3500
14 C8y C 16.4249 -15.7498
15 C8x C 15.2313 -16.4391
16 C8x C 15.2315 -17.8391
17 C8x C 16.4441 -18.5389
18 C8x C 17.6376 -17.8496
19 C8x C 17.6374 -16.4496
20 X Cl 26.6700 -14.4200
BOND 20
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 5 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 12 13 1
14 9 14 1 #Down
15 14 15 2
16 15 16 1
17 16 17 2
18 17 18 1
19 18 19 2
20 14 19 1
|
|---|
